On November 11, 10x Genomics, Inc. rose 4.71% in Pre-Market Trading, trading at $66.94 per share, with turnover of $146.6 thousand.
The move followed continued market focus on the company’s recent quarterly results, which beat expectations on both earnings and revenue and included a higher full-year revenue outlook.
In its latest quarterly report, 10x Genomics, Inc. posted a Q3 loss of $0.15 per share, better than expected losses of about $0.25 to $0.27, while revenue of $150.667 million exceeded expectations near $147.9 million to $148.0 million. The company also raised full-year revenue guidance to $625 million-$635 million from $610 million-$630 million, above the consensus estimate of $620.8 million. Recent trading has remained volatile, as the improved operating trend and guidance increase have been offset at times by post-earnings analyst target cuts.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments